TargetBeta
CA4
carbonic anhydrase 4 · also CAIV, Car4, RP17 · Carbonic anhydrases
2 programs in company-led studies act on CA4, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Acetazolamiderule | Incannex Healthcare | inhibitor | phase 2 | 22 running | CA1, CA12, CA2 | ChEMBL |
| sulthiamerule | Shionogi | inhibitor | phase 2 | 21 running | CA1, CA12, CA13, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 | ChEMBL |
Conditions their studies are in
- Sleep Apnea, Obstructive, 2 programs
- Renal Insufficiency, 1 program
- Sleep Apnea Syndromes, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 4, 2026sulthiame · Shionogi · phase 2 · NCT07857837
- Dec 31, 2026Acetazolamide · Incannex Healthcare · phase 2 · NCT06776432
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.